Effect of Sunflower Lecithin Supplementation on Meibomian Gland Function in Adults With Dry Eye Disease

NCT ID: NCT06058559

Last Updated: 2024-03-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-20

Study Completion Date

2023-10-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective study will evaluate the effect of oral sunflower lecithin dietary supplementation on meibomian gland function in adults with dry eye disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Enrolled patients in the active arm of the study (n=20) will receive a daily dose of four sunflower lecithin 1,200 mg soft-gel capsules for a duration of 90 days. Patients in the control arm (n=10) will receive four doses of a 1,000 mg placebo soft-gel capsules (containing olive oil). Patients will be evaluated for meibomian gland function and signs and symptoms of dry eye at baseline and at the end of the study using a standardized eye dryness survey (SPEED survey), Tear Breakup Time Measurement, Meibomian Gland Score, and a rapid in-office assessment of years (InflammaDry).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye Disease Meibomian Gland Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators
Double (Participant, Investigator)

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sunflower Lecithin

Total 4800 mg sunflower lecithin per day taken in 4 softgel capsules

Group Type EXPERIMENTAL

Sunflower lecithin

Intervention Type DIETARY_SUPPLEMENT

Lecithins are a group of essential phospholipids that are involved in a number of biological functions such as lipid-cholesterol transport, transmembrane signaling, and neurological function

Olive Oil

Total 4000 mg olive oil per day taken in 4 softgel capsules

Group Type PLACEBO_COMPARATOR

Olive oil

Intervention Type DIETARY_SUPPLEMENT

Extra virgin olive oil

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sunflower lecithin

Lecithins are a group of essential phospholipids that are involved in a number of biological functions such as lipid-cholesterol transport, transmembrane signaling, and neurological function

Intervention Type DIETARY_SUPPLEMENT

Olive oil

Extra virgin olive oil

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age greater than18 at the time of informed consent
* Clinical diagnosis of dry eye in both eyes
* Fluorescein tear film break-up time (TBUT) less than 10s in both eyes
* The presence of lid margin scaling, telangiectasia, collarette or meibomian gland plugging on slit-lamp examination
* Best-corrected visual acuity (BCVA, Snellen) of 20/40 or better in each eye
* Patient Evaluation of Eye Dryness (SPEED) questionnaire score \>6 to \<14
* Must understand; be willing and able, and likely to fully comply with study procedures, visit schedule, and restrictions

Exclusion Criteria

* Any pre-existing ocular disease other than dry eye disease
* Patients with inability to swallow soft gel capsules
* Severe illness, pregnancy or breastfeeding, smoking, and regular use of strongly anticholinergic drugs.
* Drastic change of food and/or food supplements within the last month.
* Other food supplement with fatty acids
* Evidence of acute ocular infection and⁄or intraocular inflammation within 1 month prior to the onset of this study.
* Ocular surgery within the last 6 months.
* Patients treated with topical ocular, steroidal or non-steroidal, anti-inflammatory treatment within the last month.
* Occlusion therapy with lacrimal or punctum plugs within the last 3 months.
* Alterations of the lacrimal drainage system
* Eyelid abnormalities
* Patients on oral tetracycline or corticosteroids
* Active allergy or infection at the ocular surface
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Virginia Lions Institute Foundation

UNKNOWN

Sponsor Role collaborator

George Washington University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Belyea, MD

Role: STUDY_CHAIR

The George Washington University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The GW Medical Faculty Associates

Washington D.C., District of Columbia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

101

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Lycopene In Preventing of Prostate Cancer
NCT00006078 COMPLETED PHASE1
Impact of Phytosterol-Rich Extract on Lipid Profile
NCT06657456 ACTIVE_NOT_RECRUITING NA